[{"arm_notes": "", "treatment_id": null, "treatment_name": "Protocol AExperimental group: 55 participants with high clinical suspicion and / or medical diagnostic confirmation of COVID-19 will receive nitric oxide inhalation at 160 parts per million (ppm) for 6 hours in the first 48 hours of hospitalization; single or fractional dose. The subjects will be followed up to 60 days after being included in this study.Control Group: 55 participants with high clinical suspicion and/or medical diagnostic confirmation of COVID-19 will be selected for follow-up and will receive only conventional treatment as stipulated by the local medical team. The subjects will be followed up to 60 days after being included in this study. Protocol BExperimental group: 75 participants with high clinical suspicion and / or medical diagnostic confirmation of COVID-19 who seek medical help in the hospital emergency and who do not yet meet the criteria for hospitalization will receive nitric oxide inhalation at 160 parts per million (ppm) for 2 hours; single or fractional dose. The subjects will be followed up to 60 days after being included in this study.Control group: 75 participants with high clinical suspicion and / or medical diagnostic confirmation of COVID-19 who seek medical help in the hospital emergency and who do not yet meet the criteria for hospitalization and will receive only conventional treatment as stipulated by the local medical team. The subjects will be followed up to 60 days after being included in this study.;D01.339.387", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 890, "treatment_name": "Nitric oxide gas", "treatment_type": "Gas inhalation", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]

[]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Experimental group: 55 participants with high clinical suspicion and / or medical diagnostic confirmation of COVID-19 will receive nitric oxide inhalation at 160 parts per million (ppm) for 6 hours in the first 48 hours of hospitalization; single or fractional dose. The subjects will be followed up to 60 days after being included in this study.Control Group: 55 participants with high clinical suspicion and/or medical diagnostic confirmation of COVID-19 will be selected for follow-up and will receive only conventional treatment as stipulated by the local medical team. The subjects will be followed up to 60 days after being included in this study.;Drug;D01.339.387", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Experimental group: 55 participants with high clinical suspicion and / or medical diagnostic confirmation of COVID-19 will receive nitric oxide inhalation at 160 parts per million (ppm) for 6 hours in the first 48 hours of hospitalization; single or fractional dose. The subjects will be followed up to 60 days after being included in this study.Control Group: 55 participants with high clinical suspicion and/or medical diagnostic confirmation of COVID-19 will be selected for follow-up and will receive only conventional treatment as stipulated by the local medical team. The subjects will be followed up to 60 days after being included in this study.;Drug;Nitric Oxide", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]